Related Experiment Videos
[Molecular genetic mechanism of the kidney cancer]
N Nakaigawa1, M Yao, T Kishida
1Department of Urology, Yokohama City University School of Medicine.
Abstract:
The oncogenic mechanisms of renal cell carcinoma(RCC) are becoming elucidated with recent advances in molecular biology. von Hipple-Lindau disease(VHL) tumor suppressor gene is mutated and inactivated frequently in clear cell type RCCs. The VHL protein forms a complex which shows a ubiquitin ligase activity. The lost of the ubiquitin ligase activity of VHL protein may be a key step for clear cell tumorigenesis. Papillary renal cell carcinomas are caused by activating mutation in the tyrosine kinase domain of the MET gene. This tumorigenic pathway is regulated by c-Src. Immunogene therapies have been started for the patients with advanced RCC. The information based on microarray and Serial Analysis of Gene Expression(SAGE) will provide novel diagnosis and therapy which focus on the tumorigenic mechanism of RCC in the near future.
Insights
Renal cell carcinoma (RCC) oncogenesis involves von Hippel-Lindau (VHL) gene inactivation in clear cell types and MET gene mutations in papillary types. Understanding these mechanisms guides new diagnostic and therapeutic strategies for advanced RCC.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Renal cell carcinoma (RCC) pathogenesis is increasingly understood through molecular biology.
- Clear cell RCC often involves mutations in the von Hippel-Lindau (VHL) tumor suppressor gene.
- Papillary RCC is linked to activating mutations in the MET tyrosine kinase gene.
Purpose of the Study:
- To elucidate the oncogenic mechanisms driving different subtypes of renal cell carcinoma.
- To identify key molecular alterations and pathways involved in RCC tumorigenesis.
- To explore the potential for novel diagnostic and therapeutic approaches based on these mechanisms.
Main Methods:
- Analysis of gene mutations, including VHL and MET.
- Investigation of protein complex formation and enzymatic activity (ubiquitin ligase).
- Utilizing microarray and Serial Analysis of Gene Expression (SAGE) data.
Main Results:
- Inactivation of the VHL tumor suppressor gene and loss of its ubiquitin ligase activity are implicated in clear cell RCC.
- Activating mutations in the MET gene's tyrosine kinase domain drive papillary RCC, regulated by c-Src.
- Immunogene therapies are being explored for advanced RCC patients.
Conclusions:
- Specific genetic alterations in VHL and MET genes define distinct RCC subtypes.
- Understanding these tumorigenic pathways is crucial for developing targeted therapies.
- Molecular profiling using microarray and SAGE holds promise for future RCC diagnosis and treatment.